Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In these two clinical trials, DS-2325a, a KLK5 inhibitor, was found to be generally safe and well tolerated in healthy volunteers, with mild and non-serious adverse events, suggesting its potential for further development as a treatment for Netherton Syndrome.

This case report highlights a persistent gynecomastia in a young man following low-dose finasteride, suggesting that the incidence may be underreported and calls for patient counseling and early intervention.

This study concluded that while both 5% topical and 1 mg oral minoxidil significantly improved hair diameter in androgenetic alopecia patients, there was no significant difference in overall effectiveness or patient satisfaction between the treatments.

This study found that among patients with inflammatory bowel disease, those with the NUDT15 mutation had a reduced tolerance for thiopurine dosage over the long term and were more likely to require hospitalization and surgery compared to those without the mutation.

In this study, researchers investigated factors predicting resistance to clomiphene citrate in women with anovulatory PCOS, identifying AMH and SHBG levels as significant indicators, but they found no reliable thresholds for predicting resistance to the standard 50 mg/day dose.

In this study conducted on rabbits, conventional blood treated with 120% sodium citrate was observed to achieve the highest platelet recovery and enrichment coefficient, while altering sodium citrate concentrate affected levels of growth factors PDGF and TGF-β1 after plasma activation.

This randomized controlled trial found that methotrexate, particularly when combined with low-dose prednisone, was effective in promoting hair regrowth in patients with alopecia areata totalis, with the combination treatment showing higher efficacy and faster results.

This case study reports intracranial hypertension in a 60-year-old woman linked to prolonged intake of low-dose Vitamin A from propolis capsules, highlighting a potential risk even at lower dosages.

This study found that a mild intramuscular dose of BOTOX increased spermatogenesis and improved sperm quality in ageing mice, suggesting potential benefits for managing male infertility.

This study found that low dose methotrexate did not increase hair loss in rheumatoid arthritis patients compared to healthy controls, and many patients even showed a reduction in hair fall over the short term.

This study observed that a combination of low-dose cyclophosphamide and vinorelbine appears safe and has promising antitumor activity in patients with metastatic breast cancer resistant to anthracyclines and taxanes, achieving a 44% objective response rate at 6 months with manageable toxicity levels.

This study found that NB-002 demonstrated clear antifungal activity and clinically significant nail clearing in subjects with distal subungual onychomycosis and ≤50% nail involvement, compared to a vehicle treatment.

The authors concluded that capecitabine and high-dose toremifene may be an effective treatment option for patients unable to undergo anthracycline or taxane therapies, based on one woman's cancer management.

This study estimated the starting dose range for a finasteride long-acting injectable formulation in humans, suggesting that 16.80 mg may be the optimal starting dose.

This study found that a low dose of finasteride over 12 weeks did not alter the lipid profile or adiposity index in atheroprone Ldlr−/− mice.

60% of women who didn't respond to 5% minoxidil for hair loss showed significant improvement with a 15% minoxidil solution.

This study found that dutasteride increased hair growth and restoration in men with androgenetic alopecia more effectively than finasteride and was well tolerated over 24 weeks.

In this study, cyproterone acetate at 2 mg daily was found to be as effective as higher doses in reducing hair growth for hirsute women over 12 months.

This study found that combining a GnRH agonist with a low-dose oral contraceptive was more effective in treating hirsutism than either agent alone and prevented hypoestrogenic side effects.

This study found that 87% of patients with stage IIA and IIB melanoma treated with low-dose alpha-interferon reported cutaneous side effects, with the most common being hair loss.

This article reviews current therapies for exocrine pancreatic insufficiency in chronic pancreatitis, highlighting the challenges in achieving optimal enzyme dosing and the potential need for treatment even in asymptomatic patients.

This article analyzes various cases of weak or low-dose endocrine effects in laboratory animals and highlights challenges in data interpretation due to variability among controls, but reports no new experimental findings.

This study found that polymeric micelle formulations significantly improved the targeted delivery of adapalene to hair follicles compared to standard Differin® products, which suggests potential advantages in treating hair follicle-related conditions and reducing side effects.

This study found that long-term weekly administration of docetaxel is feasible at doses up to 45 mg/m² per week with acceptable toxicity, and suggests further evaluation with 40 mg/m² for phase II studies.

This case report described cosmetically significant hair regrowth in a 39-year-old woman with permanent chemotherapy-induced alopecia after continuous oral minoxidil use.

This study reports that the Pfizer-BioNTech COVID-19 vaccine showed 52% protection against COVID-19 after the first dose and 95% after the second in phase 3 trials.

This study observed that methotrexate combined with low- to moderate-dose oral corticosteroids may effectively treat severe alopecia areata, though long-term maintenance is often necessary due to relapse after tapering.